JT
AVBP icon

Jupiter Topco’s ArriVent BioPharma AVBP Stock Holding History

Jupiter Topco’s Portfolio AVBP Stock Details AVBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$226K Buy
+6,500
New +$192K ﹤0.01% 2379

Other funds holding AVBP

HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Jupiter Topco's AVBP Position: Q2 2026 in Review

Jupiter Topco opened a new position in ArriVent BioPharma (AVBP) in Q2 2026: 6,500 shares worth $226K. The stake represents ﹤0.01% of the portfolio and ranks #2379 among its holdings.

141 funds tracked by Wall St. Rank hold AVBP as of Q2 2026.

  • Jupiter Topco held 6,500 shares of ArriVent BioPharma worth $226K as of Q2 2026.
  • ArriVent BioPharma was a new Jupiter Topco position in Q2 2026.
  • ArriVent BioPharma made up ﹤0.01% of Jupiter Topco's portfolio in Q2 2026, its #2379 holding.
  • 141 funds tracked by Wall St. Rank held ArriVent BioPharma as of Q2 2026.

Based on Jupiter Topco's 13F filing for Q2 2026, filed 14 Aug 2026.